The clinical potential of exhaled breath analysis for diabetes mellitus.
The clinical potential of exhaled breath analysis for diabetes mellitus.
复制标题
DOI：
10.1016/j.diabres.2012.02.006
复制
发表时间：
2012-08
影响因子：
5.1
通讯作者：
Galassetti, Pietro Renato
中科院分区：
文献类型：
--
作者：
Minh, Timothy Do Chau;Blake, Donald Ray;Galassetti, Pietro Renato
关键词：
目前人类呼吸中的各种化合物长期以来一直与病理状态（包括不受控制的糖尿病中的丙酮气味）松散相关。然而，直到最近，呼出的挥发性有机化合物（VOC）和雾化颗粒的精确测量才有可能在极低的浓度下通过几种分析方法的进步，在国际文献中详细描述，每种方法都适用于呼出化合物的特定子集。呼出的气体可能是内源性产生的（在肺道，血液或外周组织中），作为人体细胞或定植微生物的代谢副产物，或者可能作为大气污染物被吸入;越来越多的证据表明，这些分子中的几种具有不同的细胞间信号传导功能。与来源和生理作用无关，呼出的VOC是作为细胞活性/代谢的生物标志物的有吸引力的候选者，并且可以被并入未来的非侵入性临床测试设备中。事实上，最近的几项研究报告了代谢异常条件下呼出气体分布的改变以及至少在受控实验条件下对健康和糖尿病受试者在广泛血糖值范围内的葡萄糖浓度的相对准确的预测。需要在更广泛的条件下优化这种方法并在大规模试验中进行验证，以确定其过渡到实际临床应用的真正潜力。
Various compounds in present human breath have long been loosely associated with pathological states (including acetone smell in uncontrolled diabetes). Only recently, however, the precise measurement of exhaled volatile organic compounds (VOCs) and aerosolized particles was made possible at extremely low concentrations by advances in several analytical methodologies, described in detail in the international literature and each suitable for specific subsets of exhaled compounds. Exhaled gases may be generated endogenously (in the pulmonary tract, blood, or peripheral tissues), as metabolic byproducts of human cells or colonizing micro-organisms, or may be inhaled as atmospheric pollutants; growing evidence indicates that several of these molecules have distinct cell-to-cell signaling functions. Independent of origin and physiological role, exhaled VOCs are attractive candidates as biomarkers of cellular activity/metabolism, and could be incorporated in future non-invasive clinical testing devices. Indeed, several recent studies reported altered exhaled gas profiles in dysmetabolic conditions and relatively accurate predictions of glucose concentrations, at least in controlled experimental conditions, for healthy and diabetic subjects over a broad range of glycemic values. Optimization of this methodology and validation in large-scale trials under a wider range of conditions is needed to determine its true potential to transition into practical clinical use.
登录
查看更多内容
DOI：
10.1016/j.jchromb.2004.05.015
发表时间：
2004-09-05
影响因子：
3
作者：
Deng, CH;Zhang, XM;Li, N
通讯作者：
Li, N
DOI：
10.1016/j.beem.2005.04.001
发表时间：
2005-09-01
影响因子：
7.4
作者：
Blaak, EE
通讯作者：
Blaak, EE
影响因子：
5.4
作者：
Greiter, M. B.;Keck, L.;Paretzke, H. G.
通讯作者：
Paretzke, H. G.
影响因子：
4.4
作者：
Cummins, Eoin P.;Oliver, Kathryn M.;Taylor, Cormac T.
通讯作者：
Taylor, Cormac T.
影响因子：
16.2
作者：
American Diabetes Association
通讯作者：
American Diabetes Association